Tumor genomes were classified as either BRCA1-deficient, BRCA2-deficient or BRCA-proficient, which incorporated germline and somatic alterations in BRCA1 and BRCA2, as well as other well-defined HR genes, and tumor HRD status as determined by a mutational signature-based classifier (CHORD, Classifier of HOmologous Recombination Deficiency)60 (Supplementary Information and Supplementary Tables S10-S12). Here, BRCA2 is linked to neoplasm.